This self-assessment tool has been developed to help trust teams assess and provide board-level assurance on the safety, quality and delivery of non-elective care in the first 72 hours in hospital, ...

In order to move forward, it is expected that existing data from the Phase 2b/3 Anavex 2-73 AD-004 program be submitted to the FDA. In December, as expected, the CHMP adopted a negative opinion on the ...